AR090080A1 - Formulaciones de nanoparticulas termosensibles y metodo para elaborarlas - Google Patents

Formulaciones de nanoparticulas termosensibles y metodo para elaborarlas

Info

Publication number
AR090080A1
AR090080A1 ARP130100494A ARP130100494A AR090080A1 AR 090080 A1 AR090080 A1 AR 090080A1 AR P130100494 A ARP130100494 A AR P130100494A AR P130100494 A ARP130100494 A AR P130100494A AR 090080 A1 AR090080 A1 AR 090080A1
Authority
AR
Argentina
Prior art keywords
phosphatidyl
liposomes
monoacrylic
approximately
lipid bilayer
Prior art date
Application number
ARP130100494A
Other languages
English (en)
Original Assignee
Celsion Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celsion Corp filed Critical Celsion Corp
Publication of AR090080A1 publication Critical patent/AR090080A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1277—Processes for preparing; Proliposomes
    • A61K9/1278—Post-loading, e.g. by ion or pH gradient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Dispersion Chemistry (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Una formulación de liposomas termosensibles y, más específicamente, a una formulación de liposomas que comprende fosfolípidos y un agente tensioactivo, donde los liposomas toleran el almacenamiento a largo plazo a temperaturas menores que -o iguales a- 8ºC, aproximadamente; controlan la formación de degradados para maximizar la potencia del producto y liberan su contenido a temperaturas moderadamente hipertérmicas. También se describen los métodos para elaborar las formulaciones. Reivindicación 1: Una preparación liposomal, que comprende una suspensión de liposomas que tiene una bicapa lipídica en fase en gel y un agente activo atrapado dentro de los liposomas; dicha bicapa lipídica comprende: (i) uno o más fosfolípidos seleccionados del grupo que consiste de fosfatidil-colinas, fosfatidil-gliceroles, fosfatidil-inositoles y fosfatidil-etanolaminas; (ii) uno o más fosfolípidos derivados con un polímero hidrófilo; y (iii) uno o más lisolípidos que se seleccionan del grupo que consiste de monoacilfosfatidil-colinas, monoacilfosfatidil-gliceroles, monoacilfosfatidil- inositoles y monoacilfosfatidil-etanolaminas; donde los constituyentes de la bicapa lipídica se proporcionan en una relación molar de aproximadamente 80-90:2-8:2-18; y donde el tamaño de los liposomas en la suspensión es de entre aproximadamente 50 y aproximadamente 150 nm; y donde la concentración relativa de la impureza A después de 6 meses de almacenamiento a una temperatura menor que -o igual a- 8ºC es inferior a 0,5%, y donde la impureza A es un pico con un tiempo de retención relativo de aproximadamente 1,4 en una cromatografía líquida de alto rendimiento (HPLC) con una columna en fase inversa C18 y condiciones de elusión en gradiente con ácido acético/solvente de metanol. Reivindicación 2: La preparación liposomal de la reivindicación 1, donde el agente activo es doxorrubicina. Reivindicación 17: La composición farmacéutica de la reivindicación 2, donde los liposomas también comprenden un agente para la formación de imágenes o un agente de diagnóstico.
ARP130100494A 2012-02-17 2013-02-18 Formulaciones de nanoparticulas termosensibles y metodo para elaborarlas AR090080A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201261600418P 2012-02-17 2012-02-17

Publications (1)

Publication Number Publication Date
AR090080A1 true AR090080A1 (es) 2014-10-15

Family

ID=48984771

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP130100494A AR090080A1 (es) 2012-02-17 2013-02-18 Formulaciones de nanoparticulas termosensibles y metodo para elaborarlas

Country Status (16)

Country Link
US (2) US20130230457A1 (es)
EP (1) EP2814464B1 (es)
JP (3) JP2015507019A (es)
KR (1) KR102161271B1 (es)
CN (2) CN104203216A (es)
AR (1) AR090080A1 (es)
AU (1) AU2013221292A1 (es)
CA (1) CA2864469C (es)
ES (1) ES2773299T3 (es)
HK (1) HK1200733A1 (es)
MX (1) MX2014009827A (es)
PH (1) PH12014501866A1 (es)
RU (1) RU2014133467A (es)
SG (1) SG11201404979RA (es)
TW (2) TWI684463B (es)
WO (1) WO2013123407A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2971010B1 (en) 2013-03-14 2020-06-10 ModernaTX, Inc. Formulation and delivery of modified nucleoside, nucleotide, and nucleic acid compositions
EP3041934A1 (en) 2013-09-03 2016-07-13 Moderna Therapeutics, Inc. Chimeric polynucleotides
WO2015034925A1 (en) 2013-09-03 2015-03-12 Moderna Therapeutics, Inc. Circular polynucleotides
EP3171895A1 (en) 2014-07-23 2017-05-31 Modernatx, Inc. Modified polynucleotides for the production of intrabodies
ES2826896T3 (es) * 2015-05-04 2021-05-19 Versantis AG Método para preparar vesículas con gradiente de pH transmembrana
GB201509934D0 (en) * 2015-06-08 2015-07-22 King S College London Nanoparticles
TWI678213B (zh) 2015-07-22 2019-12-01 美商史倍壯製藥公司 用於長春新鹼硫酸鹽脂質體注射之即可使用的調配物
CN105078892B (zh) * 2015-09-06 2018-05-01 重庆医科大学 阿苯达唑热敏脂质体的制备方法
WO2017078009A1 (ja) * 2015-11-02 2017-05-11 富士フイルム株式会社 リポソーム組成物およびその製造方法

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4880635B1 (en) * 1984-08-08 1996-07-02 Liposome Company Dehydrated liposomes
IT1230505B (it) * 1988-10-11 1991-10-25 Sicor Spa Procedimento per la conversione della daunorubicina in doxorubicina.
US5013556A (en) * 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US6214388B1 (en) * 1994-11-09 2001-04-10 The Regents Of The University Of California Immunoliposomes that optimize internalization into target cells
CA2269758C (en) * 1996-10-22 2008-01-08 Hermes Biosciences, Inc. Liposome compositions comprising ionizable compounds in stable precipitated form and methods for their preparation
US6726925B1 (en) * 1998-06-18 2004-04-27 Duke University Temperature-sensitive liposomal formulation
US6200598B1 (en) * 1998-06-18 2001-03-13 Duke University Temperature-sensitive liposomal formulation
US6593308B2 (en) * 1999-12-03 2003-07-15 The Regents Of The University Of California Targeted drug delivery with a hyaluronan ligand
CN1236760C (zh) * 2000-01-28 2006-01-18 阿尔萨公司 含有存在于过饱和溶液中的包载化合物的脂质体
US20020028237A1 (en) * 2000-04-20 2002-03-07 Colbern Gail T. Method for reducing toxicity of a cytotoxic agent
US8980310B2 (en) * 2002-12-31 2015-03-17 Bharat Serums and Vaccines, Ltd. Non-pegylated long-circulating liposomes
US20060222694A1 (en) * 2003-06-27 2006-10-05 Oh Choon K Stabilized topotecan liposomal composition and methods
EP1689364A4 (en) * 2003-11-20 2008-10-29 Ym Biosciences Inc STABLE LIPOSOMAL COMPOSITIONS COMPRISING LIPOPHILIC AMINE CONTAINING PHARMACEUTICAL AGENTS
US20080058274A1 (en) * 2004-11-15 2008-03-06 Yechezkel Barenholz Combination Therapy
US20060127467A1 (en) * 2004-12-14 2006-06-15 Watkin Kenneth L Nanoparticles for delivery of therapeutic agents using ultrasound and associated methods
TWI388344B (zh) * 2005-08-23 2013-03-11 Celsion Corp 儲存奈米微粒調合物之方法
US20080261913A1 (en) * 2006-12-28 2008-10-23 Idenix Pharmaceuticals, Inc. Compounds and pharmaceutical compositions for the treatment of liver disorders
CA2700810A1 (en) * 2007-09-28 2009-04-02 Universitatsspital Basel Immunoliposomes for treatment of cancer
WO2009059449A1 (en) 2007-11-05 2009-05-14 Celsion Corporation Novel thermosensitive liposomes containing therapeutic agents
WO2009059450A1 (en) * 2007-11-05 2009-05-14 Shanghai Jiaotong University Peptide ligand directed drug delivery
EP2219587A4 (en) * 2007-11-14 2012-11-21 Univ California STEROL-MODIFIED AMPHIPHILE LIPIDES
TWI397428B (zh) * 2009-12-29 2013-06-01 Ind Tech Res Inst 標的第四介白素受體之傳輸系統
WO2011109334A2 (en) * 2010-03-01 2011-09-09 The Regents Of The University Of California Localization of agents at a target site with a composition and an energy source
EP2670393B8 (en) * 2011-01-31 2016-10-05 Nanobiotix Method of monitoring the release from liposomes of a product of interest using superparamagnetic nanoparticles.

Also Published As

Publication number Publication date
JP2020050681A (ja) 2020-04-02
KR20140126381A (ko) 2014-10-30
AU2013221292A1 (en) 2014-09-11
TW201345565A (zh) 2013-11-16
US20130230457A1 (en) 2013-09-05
KR102161271B1 (ko) 2020-09-29
EP2814464A4 (en) 2015-08-05
JP2018058858A (ja) 2018-04-12
EP2814464A1 (en) 2014-12-24
JP6824452B2 (ja) 2021-02-03
CN104203216A (zh) 2014-12-10
EP2814464B1 (en) 2019-12-18
CA2864469C (en) 2020-07-07
ES2773299T3 (es) 2020-07-10
RU2014133467A (ru) 2016-04-10
WO2013123407A1 (en) 2013-08-22
JP2015507019A (ja) 2015-03-05
CN106727329A (zh) 2017-05-31
PH12014501866A1 (en) 2014-11-17
CA2864469A1 (en) 2013-08-22
US10251901B2 (en) 2019-04-09
SG11201404979RA (en) 2014-10-30
TW201841622A (zh) 2018-12-01
HK1200733A1 (en) 2015-08-14
CN106727329B (zh) 2020-11-03
US20170080003A1 (en) 2017-03-23
TWI637754B (zh) 2018-10-11
MX2014009827A (es) 2014-09-22
TWI684463B (zh) 2020-02-11

Similar Documents

Publication Publication Date Title
AR090080A1 (es) Formulaciones de nanoparticulas termosensibles y metodo para elaborarlas
Zhao et al. Selection of high efficient transdermal lipid vesicle for curcumin skin delivery
Natsheh et al. Phospholipid vesicles for dermal/transdermal and nasal administration of active molecules: The effect of surfactants and alcohols on the fluidity of their lipid bilayers and penetration enhancement properties
Yücel et al. Anti-aging formulation of rosmarinic acid-loaded ethosomes and liposomes
Junyaprasert et al. Physicochemical properties and skin permeation of Span 60/Tween 60 niosomes of ellagic acid
Andrade et al. Impact of lipid dynamic behavior on physical stability, in vitro release and skin permeation of genistein-loaded lipid nanoparticles
US9968583B2 (en) Method of manufacture of liposome composition
Manca et al. Glycerosomes: Investigation of role of 1, 2-dimyristoyl-sn-glycero-3-phosphatidycholine (DMPC) on the assembling and skin delivery performances
Kawadkar et al. Formulation, characterization and in vitro–in vivo evaluation of flurbiprofen-loaded nanostructured lipid carriers for transdermal delivery
US20160279073A1 (en) Terpene and cannabinoid formulations
Lu et al. Application of liposome encapsulation technique to improve anti-carcinoma effect of resveratrol
Shakeel et al. Skin permeation mechanism of aceclofenac using novel nanoemulsion formulation
NZ596657A (en) Self micro-emulsifying oral pharmaceutical composition of hydrophilic drug and preparation method thereof
Junyaprasert et al. Influence of chemical penetration enhancers on skin permeability of ellagic acid-loaded niosomes
Huang et al. A novel hyaluronic acid-based dissolving microneedle patch loaded with ginsenoside Rg3 liposome for effectively alleviate psoriasis
BR112013024663A2 (pt) composição de lipossomas de liberação controlada de longa duração e método para produção da mesma
Ma et al. In vivo fate of biomimetic mixed micelles as nanocarriers for bioavailability enhancement of lipid–drug conjugates
Yang et al. Preparation and evaluation of microemulsion‑based transdermal delivery of Cistanche tubulosa phenylethanoid glycosides
Chen et al. The freeze-thawed and freeze-dried stability of cytarabine-encapsulated multivesicular liposomes
Ali et al. Recent developments in ionic liquid-assisted topical and transdermal drug delivery
Lapteva et al. Microstructured bicontinuous phase formulations: their characterization and application in dermal and transdermal drug delivery
CN101953792A (zh) 伊立替康纳米长循环脂质体及其制备方法
Singh et al. Topical non steroidal anti inflammatory drug (NSAIDs) microemulsions: Rationale, review and future prospective
Alexopoulou et al. Preparation and characterization of lyophilized liposomes with incorporated quercetin
Esparza et al. Development of co-solvent freeze-drying method for the encapsulation of water-insoluble thiostrepton in sterically stabilized micelles

Legal Events

Date Code Title Description
FB Suspension of granting procedure